Protagonist Therapeutics, Inc
ICOTYDE
psoriatic arthritis, ulcerative colitis, Crohn’s disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for ICOTYDE in psoriatic arthritis, ulcerative colitis, Crohn’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further develop”